Livongo pulls down $45m Series C for digital diabetes program
Livongo Health said today that it raised nearly $45 million in a Series C round it plans to use to grow the footprint of its digital diabetes management program. Livongo said the $44.5 million round included new investors Merck‘s (NYSE:MRK) Global Health Innovation Fund, Cowen Private Investments, Sapphire Ventures, Blue Cross Blue Shield of Massachusetts’ investment arm Zaffre Investments and Wanxiang America Corp. Existing backers General Catalyst, Kleiner Perkins Caufield & Byers, DFJ and 7wire Ventures also participated, the Mountain View, Calif.-based company said. Livongo said it plans to use the cash to expand the diabetes program and to move into other chronic health markets.